143 related articles for article (PubMed ID: 19488035)
1. Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies.
Snyder EL; Bailey D; Shipitsin M; Polyak K; Loda M
Lab Invest; 2009 Aug; 89(8):857-66. PubMed ID: 19488035
[TBL] [Abstract][Full Text] [Related]
2. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
3. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
Adamczyk A; Niemiec JA; Ambicka A; Mucha-Małecka A; Mituś J; Ryś J
J Mol Histol; 2014 Feb; 45(1):35-45. PubMed ID: 23835592
[TBL] [Abstract][Full Text] [Related]
4. In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas.
Perrone G; Gaeta LM; Zagami M; Nasorri F; Coppola R; Borzomati D; Bartolozzi F; Altomare V; Trodella L; Tonini G; Santini D; Cavani A; Muda AO
PLoS One; 2012; 7(9):e43110. PubMed ID: 23028444
[TBL] [Abstract][Full Text] [Related]
5. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer.
Camerlingo R; Ferraro GA; De Francesco F; Romano M; Nicoletti G; Di Bonito M; Rinaldo M; D'Andrea F; Pirozzi G
Oncol Rep; 2014 Mar; 31(3):1127-32. PubMed ID: 24366074
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
7. Mammary stem cells and breast cancer--role of Notch signalling.
Farnie G; Clarke RB
Stem Cell Rev; 2007 Jun; 3(2):169-75. PubMed ID: 17873349
[TBL] [Abstract][Full Text] [Related]
8. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
9. Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: a preclinical study.
Vermeulen JF; van Brussel AS; Adams A; Mali WP; van der Wall E; van Diest PJ; Derksen PW
Mol Imaging Biol; 2013 Jun; 15(3):290-8. PubMed ID: 23184608
[TBL] [Abstract][Full Text] [Related]
10. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
12. A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer.
Ahmed MA; Aleskandarany MA; Rakha EA; Moustafa RZ; Benhasouna A; Nolan C; Green AR; Ilyas M; Ellis IO
Breast Cancer Res Treat; 2012 Jun; 133(3):979-95. PubMed ID: 22119938
[TBL] [Abstract][Full Text] [Related]
13. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.
Wright MH; Calcagno AM; Salcido CD; Carlson MD; Ambudkar SV; Varticovski L
Breast Cancer Res; 2008; 10(1):R10. PubMed ID: 18241344
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer stromal fibroblasts promote the generation of CD44+CD24- cells through SDF-1/CXCR4 interaction.
Huang M; Li Y; Zhang H; Nan F
J Exp Clin Cancer Res; 2010 Jun; 29(1):80. PubMed ID: 20569497
[TBL] [Abstract][Full Text] [Related]
15. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.
Giatromanolaki A; Sivridis E; Fiska A; Koukourakis MI
Med Oncol; 2011 Sep; 28(3):745-52. PubMed ID: 20405247
[TBL] [Abstract][Full Text] [Related]
16. [Expression of CD44 variant v6 in breast carcinoma and its relationship with other parameters of tumor biology].
Aceituno E; Turrión F; San Román JM; Sarasa JL; Ortiz F; García R
Med Clin (Barc); 1998 Jul; 111(5):168-71. PubMed ID: 9732832
[TBL] [Abstract][Full Text] [Related]
17. Association of CD44
Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line.
Rappa G; Lorico A
Exp Cell Res; 2010 May; 316(9):1576-86. PubMed ID: 20074564
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
[TBL] [Abstract][Full Text] [Related]
20. [Pilot study on the correlation between high incidence of CD44+/CD24 -/low/ABCG2- cells and poor prognosis in breast cancer].
Gong JF; Yuan YH; Song GH; Yu J; Han Y; Jia J; Ren J
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Oct; 40(5):465-70. PubMed ID: 18931706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
